News

France 2nd in the world?
Enlarge image

StudyFrance

France 2nd in the world?

24.05.2012 - France Biotech has presented its 2011 biotech survey together with France Biotech. The results are very favorable for the country.

Paris – The data of the Life Science Panorama 2010/11 survey provided by Ernst & Young claim a leading role for French biotechnology in the world. The accounting specialist has found an impressive number of 1,359 life science companies that are active in France, ranking the country 2nd in the world in terms of the number of such companies. However, the survey gives no clear criteria for the selection of the firms included. Other studies use clearly defined and internationally comparable criteria defined by the OECD. Furthermore, Ernst & Young only surveyed only about 200 companies. 103 firms responded. On this basis, Ernst & Young calculated annual revenues of €261 million in France. In comparison, a report from biotechnologie.de conform to OECD criteria found 552 biotech companies in Germany with €2.4bn in sales. As in Europe, the amount of private equity available for biotechs dropped sharply in France between 2010 and 2011 from €460m to €277m according to Ernst & Young, while the number of start ups founded balanced the number of companies liquidated (24 versus 25). However, the lack of private money could be largely compensated by state programmes such as the FSI-PME programme.  France also expanded its product pipeline. According to the report, 320 therapeutic products were in development whilst 20 were already being marketed in 2011. On top of that, diagnostic companies sold 59 in-vitro diagnostics and 21 in-vivo diagnostics. 

According to the report, the first foreign acquisitions by French companies took place in 2011. Swedish Cellartis AB was bought by Paris-based Cellectis S.A. and SC World Inc. from Japan by Vivalis SA (Nantes). In return, two French companies were acquired by foreign enterprises, namely Novagali Pharma S.A. (Évry) by Santen Pharmaceutical Co. Ltd. (Japan) and Ipsogen SA (Marseille) by Qiagen N.V. (Netherlands). 

http://www.european-biotechnology-news.com/news/news/2012-02/french-life-sciences-ranked-2nd-in-the-world.html

2014EU

19.12.2014 We took a look back at 2014: which European Biotechnology News stories topped the charts this year?

R&DEUBelgium

18.12.2014 IMI has launched a €115m call for proposals involving a project in collaboration with the Bill and Melinda Gates Foundation to improve vaccines against whopping cough in children.

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

Events

All Events

Current issue

All issues

Product of the week

Products